Spots Global Cancer Trial Database for relapsed adult aml
Every month we try and update this database with for relapsed adult aml cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia | NCT06022003 | AML, Adult Refractory AML Relapsed Adult ... FLT3-TKD Mutati... FLT3-ITD | AzaCITIDine Ora... Xospata | 18 Years - | French Innovative Leukemia Organisation | |
| Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia | NCT06022003 | AML, Adult Refractory AML Relapsed Adult ... FLT3-TKD Mutati... FLT3-ITD | AzaCITIDine Ora... Xospata | 18 Years - | French Innovative Leukemia Organisation | |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) | NCT03091933 | Hematologic Can... Relapse Leukemi... Relapsed Adult ... Relapsed Adult ... Relapsed CLL Relapsed Non Ho... Relapsed Hodgki... Relapsed Myelod... Relapsed Multip... | GLIDE | 18 Years - 65 Years | Ciusss de L'Est de l'Île de Montréal | |
| Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT | NCT06141304 | Relapsed Adult ... Relapsed Adult ... | Plerixafor | 14 Years - 60 Years | The First Hospital of Jilin University | |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) | NCT03091933 | Hematologic Can... Relapse Leukemi... Relapsed Adult ... Relapsed Adult ... Relapsed CLL Relapsed Non Ho... Relapsed Hodgki... Relapsed Myelod... Relapsed Multip... | GLIDE | 18 Years - 65 Years | Ciusss de L'Est de l'Île de Montréal | |
| Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT06007911 | Relapsed Adult ... Refractory AML | Navitoclax Dose... Navitoclax Dose... Navitoclax Dose... Navitoclax Dose... Venetoclax Dose... Venetoclax Dose... Cladribine Cytarabine (Cla... Cytarabine (CLA... Mitoxantrone Granulocyte Col... | 18 Years - | Medical College of Wisconsin | |
| New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | NCT05029141 | Acute Myeloid L... Refractory Acut... Relapsed Adult ... | CAHAG regimen Placebo regimen | 18 Years - 69 Years | The First Affiliated Hospital of Soochow University | |
| Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation | NCT03245424 | Acute Myeloid L... Relapsed Adult ... Relapsed Pediat... | ivosidenib (AG-... | 12 Years - | Agios Pharmaceuticals, Inc. | |
| Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT | NCT06141304 | Relapsed Adult ... Relapsed Adult ... | Plerixafor | 14 Years - 60 Years | The First Hospital of Jilin University | |
| Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia | NCT05237258 | Relapsed Adult ... Primary Refract... High Risk Acute... | Specialty Palli... Primary Palliat... | 18 Years - 120 Years | Massachusetts General Hospital | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia | NCT05237258 | Relapsed Adult ... Primary Refract... High Risk Acute... | Specialty Palli... Primary Palliat... | 18 Years - 120 Years | Massachusetts General Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
